The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | The current treatment landscape for SCLC
Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of current first and second line therapies for small cell lung cancer (SCLC). Chemotherapy has previously been the only treatment available in the frontline setting but the IMpower133 (NCT02763579) and CASPIAN (NCT03043872) trials have enabled the approval of the anti-PD-L1 antibodies atezolizumab and durvalumab respectively with chemotherapy. Whilst nivolumab and pembrolizumab have additionally been approved in the second line setting, lurbinectedin and topotecan have become the standard of care. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
